Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.54% | 26.14% | 26.82% | 12.42% | 2.39% |
| Total Depreciation and Amortization | -25.22% | -28.55% | -31.96% | -23.03% | -16.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.25% | -56.63% | -54.57% | 18.46% | 67.93% |
| Change in Net Operating Assets | 21.29% | 45.48% | -91.06% | -58.21% | 59.94% |
| Cash from Operations | 11.82% | 16.41% | 13.66% | 16.05% | 17.75% |
| Capital Expenditure | -17.87% | -171.52% | -715.48% | -497.66% | -256.85% |
| Sale of Property, Plant, and Equipment | 96.72% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.30% | 145.36% | 801.74% | 212.32% | 224.65% |
| Cash from Investing | -21.25% | 145.04% | 809.85% | 206.00% | 224.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 23.21% | 8.28% | -78.10% | -68.41% | -79.69% |
| Cash from Financing | 32.46% | 24.66% | -94.50% | -92.82% | -95.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,355.83% | 93.21% | 198.22% | 823.47% | 93.75% |